Founded in 2017 and headquartered in Suzhou, 信诺维 is a platform-oriented innovative drug company focused on addressing major unmet clinical needs. The company has built proprietary platforms in targeted therapy, anti-infection agents and PROTACs and has formed leading global pipelines including BLI inhibitors, EZH2 inhibitors, hURAT1 inhibitors and next-generation ADCs. It currently has nine products in domestic and international clinical development, with two programs in Phase III and several in Phase I–II. Lead anti-infective XNW4107 is in a global multi-center pivotal Phase III trial targeting carbapenem-resistant pathogens; XNW3009 (urate-lowering) is in Phase III and showed superior urate-lowering vs comparators in randomized double-blind trials. Oncology programs include EZH2 inhibitor XNW5004 (Phase II) with a collaboration with MSD and combination trials with a “K” drug, and next-gen ADCs XNW27/XNW28 in Phase I. The company has completed multiple out-licenses with aggregate amounts described as 数十亿美元 and has raised cumulative financing exceeding ¥2 billion RMB to date. 信诺维 is an innovative pharmaceutical company founded in 2017 that focuses on addressing major unmet clinical needs and holds global intellectual property. Headquartered in Suzhou, the company has branches in Beijing, Shanghai, Australia and Boston and has received regional awards and recognitions. Its pipeline targets both Best‑in‑Class and First‑in‑Class programs across oncology, anti‑infectives, autoimmune and metabolic diseases, with five products in clinical stages and three in IND‑enabling stages. In December 2020 the company completed a several‑hundred‑million‑RMB Pre‑IPO financing led by Haishong Capital with participation from China Development Capital, Jiuyou Capital, Fengyi Yuanda Capital, Agricultural Bank International and Deguang Capital. Proceeds will be used to advance domestic and international clinical trials and to construct a new drug production base. The company has built a comprehensive team of industry professionals and expects the new manufacturing base to accelerate product commercialization and attract additional biopharma talent to the region.

Total raised

$97M

Funding rounds

2

Latest round

Series E

Latest activity

Feb 2024